AbstractThis article examines a paradox. India has received worldwide recognition as a low-cost producer of high-quality drugs. This has contributed to accessibility of drugs abroad and reflects strong innovative capabilities developed in India. Yet at home, most Indian people do not have regular access to essential medicines. The contrast between the success of Indian industrial policy in developing the industry and the failure of Indian health
policy in ensuring access to drugs demonstrates starkly the need for
integration of industrial and health policies if safe universal access to essential medicines is to be achieved.Cet article analyse un paradoxe. L'Inde est connue pour sa capacité à produire des médicaments de bonne qualité à bas prix. Cela a contribué
à rendre ces produits plus accessibles aux populations de différents pays. Cependant, les populations indiennes ont des difficultés à accéder aux médicaments essentiels. Le contraste entre l'agressivité de la
politiqueindustrielle et l'incapacité des services de santé à fournir un accès équitable aux médicaments montre le besoin d'intégrer ces deux
dimensions si l'on veut plus d'équité en matière d'accès aux soins.
[1]
Huck-ju Kwon,et al.
The Political Economy of National Health Insurance in Korea
,
2005
.
[2]
Els Torreele,et al.
Drug development for neglected diseases: a deficient market and a public-health policy failure
,
2002,
The Lancet.
[3]
A. Phadke.
Drug Supply and Use: Towards a Rational Policy in India
,
1998
.
[4]
P. Munderi.
Interim Report of Task Force 5 Working Group on Access to Essential Medicines
,
2004
.
[5]
H S Luft,et al.
Competition and regulation.
,
1985,
Medical care.
[6]
G. Chellaraj,et al.
The Indian Pharmaceutical Sector: Issues and Options for Health Sector Reform
,
2002
.
[7]
J. Nogués.
Patents and Pharmaceutical Drugs: Understanding the Pressures on Developing Countries
,
1990,
Journal of World Trade.